Rare diseases
Investigational molecules
Locations
Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
AustriaLong‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors
BelgiumStudy of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors
BelgiumPhase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors
BelgiumA study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations
DenmarkA study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.
GermanyA study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations
FinlandEvaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma
BelgiumA study to test the safety and effects of TLN-372 alone and with other cancer drugs in patients with advanced solid tumors with KRAS gene changes
SpainComparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment
ItalyComparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer
GermanyA Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change
DenmarkTell us about your condition – we search every trial in Europe and connect you with the right site.
